← Back to Search

E-Cigarette Variations for Youth Vaping Behavior

N/A
Waitlist Available
Led By Marielle Brinkman, BS
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 5, 10, 35 min.
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at how nicotine form, concentration, and flavor affects youth vaping behavior and health.

Who is the study for?
This trial is for young adults aged 21-25 who exclusively use e-cigarettes daily for the last 3 months. Participants must abstain from all tobacco and nicotine for 12 hours before lab sessions, commit to five lab visits, and not be pregnant or breastfeeding. Those with unstable psychiatric conditions, recent heart issues, frequent marijuana use, other tobacco product use, or lung diseases like asthma are excluded.
What is being tested?
The study investigates how different forms of nicotine in e-cigarettes (varying in concentration and flavor) affect vaping habits and health outcomes in youth. It involves multiple lab sessions where participants' responses to these variations are observed.
What are the potential side effects?
While specific side effects aren't listed here, potential risks may include throat irritation, coughing, dry mouth or throat; increased heart rate or blood pressure; headaches; dizziness; nausea; changes in taste perception.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 5, 10, 35 min.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 5, 10, 35 min. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Airway Inflammation (NIOX VERO)
Average Puff Duration
Average Puff Volume
+3 more
Secondary study objectives
Drug Effects/Liking Questionnaire
E-cigarette Purchase Task - Breakpoint
Modified Cigarette Dependence Scale
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

8Treatment groups
Experimental Treatment
Group I: Low concentration nicotine salt (1%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group II: Low concentration nicotine salt (1%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group III: Low concentration free-base nicotine (1%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group IV: Low concentration free-base nicotine (1%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group V: High concentration nicotine salt (5%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VI: High concentration nicotine salt (5%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VII: High concentration free-base nicotine (5%), Tobacco flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
Group VIII: High concentration free-base nicotine (5%), Menthol flavorExperimental Treatment1 Intervention
Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
342 Previous Clinical Trials
293,119 Total Patients Enrolled
Marielle Brinkman, BSPrincipal InvestigatorOhio State University
Theodore L Wagener, PhDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
4 Previous Clinical Trials
2,002 Total Patients Enrolled

Media Library

ECIG lab session 2 Clinical Trial Eligibility Overview. Trial Name: NCT05458895 — N/A
E-Cigarette Use Research Study Groups: Low concentration free-base nicotine (1%), Tobacco flavor, High concentration free-base nicotine (5%), Tobacco flavor, High concentration nicotine salt (5%), Tobacco flavor, Low concentration nicotine salt (1%), Tobacco flavor, High concentration free-base nicotine (5%), Menthol flavor, High concentration nicotine salt (5%), Menthol flavor, Low concentration free-base nicotine (1%), Menthol flavor, Low concentration nicotine salt (1%), Menthol flavor
E-Cigarette Use Clinical Trial 2023: ECIG lab session 2 Highlights & Side Effects. Trial Name: NCT05458895 — N/A
ECIG lab session 2 2023 Treatment Timeline for Medical Study. Trial Name: NCT05458895 — N/A
~22 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top